Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims 1-9, are pending in this application.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 2, 4-8, are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Comprise(s), e.g. claims 2, line 2, is an open-ended term implying other allergic symptoms not cited in the claim are claimed. Hence, the claims 2, 4-8, are indefinite. Replacing comprise(s) with “is”, in every occurrence will obviate the rejection.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-9, are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chen, CN 116585321 A (filed date 2/21/23), which teaches a composition comprising ganciclovir for treating allergic rhinitis, wherein the subject has rhinocleisis, rhinocnesmus, sneezing or rhinorrhea (fig. 2). The prior art teaches administering the composition alone or in combination with another allergic rhinitis medicine (summary of invention). The administration can be oral, in form of capsules, granules, tablets, pulvis, etc. or by nasal spray. The administration is for 7-14 days followed by another allergic rhinitis medicine for 7-14 days (summary of invention). The other medicine can be a nasal spray hormone, and an oral antihistamine selected from the list in summary of invention. The dose is 250-500 mg, twice daily for a 14-year old and above, while it is 125-250 mg, twice daily for under 14 years old. See also the entire document, particularly the abstract, summary of invention, treatment examples, and figure 2.
IDS
No IDS was filed in this application. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." See the MPEP 2000 and 37 CFR 1.97, 1.98. The references and English translations of all foreign documents must be submitted.
Telephone Inquiry
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, whose telephone number is (571) 272-0709.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Andy Kosar, can be reached on (571) 272-0913. The fax phone number for this Group is (571) 273-8300.
Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.
/TAOFIQ A SOLOLA/Primary Examiner, Art Unit 1625
October 28, 2025